Table 1.
Demographics and baseline disease characteristics
| Risankizumab (N = 244) | |
|---|---|
| Age (years), median (range) | 50 (21–81) |
| Age categories (years), n (%) | |
| < 40 | 65 (26.6) |
| 40 to 65 | 150 (61.5) |
| ≥ 65 | 29 (11.9) |
| Sex, n (%) | |
| Female | 63 (25.8) |
| Male | 181 (74.2) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 17 (7.0) |
| Not Hispanic or Latino | 227 (93.0) |
| Race1, n (%) | |
| American Indian or Alaska Native | 1 (0.4) |
| Asian | 27 (11.1) |
| Black or African-American | 1 (0.4) |
| Multiple race2 | 1 (0.4) |
| Native Hawaiian or Pacific Islander | 0 |
| White | 214 (87.7) |
| Weight (kg), mean (SD) | 93.4 (22.1) |
| Weight (kg), n (%) | |
| ≤ 100 | 173 (70.9) |
| > 100 | 71 (29.1) |
| BMI (kg/m2), mean (SD) | 30.9 (6.7) |
| BMI (kg/m2), n (%) | |
| < 25 | 42 (17.2) |
| ≥ 25 to < 30 | 86 (35.2) |
| ≥ 30 | 116 (47.5) |
| sPGA category, n (%) | |
| 2 | 129 (52.9) |
| 3 | 115 (47.1) |
| PASI, mean (SD) | 6.5 (2.8) |
| BSA, mean (SD) | 6.1 (2.3) |
| PSS, mean (SD) | 6.7 (3.8) |
| DLQI, mean (SD) | 8.7 (6.7) |
| Duration of plaque psoriasis (in years), mean (SD) | 21.3 (13.6) |
| Immediate prior treatment, n (%) | |
| Secukinumab | 149 (61.1) |
| Ixekizumab | 95 (38.9) |
| Duration of last treatment prior to switching to risankizumab (in years), median (range) | |
| Secukinumab | 2.4 (0.2–9.4) |
| Ixekizumab | 1.6 (0.4–13.6) |
| Number of prior biologic therapies, n (%) | |
| ≤ 2 | 142 (58.2) |
| > 2 | 102 (41.8) |
| Prior biologic therapy (inadequate response), n (%) | 217 (88.9) |
| History of psoriatic arthritis | 12 (4.9) |
| History of IBD | 1 (0.4) |
BMI body mass index, BSA body surface area; DLQI Dermatology Life Quality Index; IBD inflammatory bowel disease; PASI Psoriasis Area and Severity Index; SD standard deviation. 1Data for race and ethnicity were self-reported. 2Patients who chose more than one category were placed in the 'multiple' category